Sudha Ramalingam*, Shanmugasundaram R, Tamil Arasu K, Rajendiran G, Meenu S, Ramalingam Sankaran*
Ramalingam et al. J Clin Transl Res 2021; 7(4):10
Published online: July 30, 2021
Abstract
Background and aim: The incidence of heart failure (HF) is rising to epidemic proportions in developing countries like India. A lack of adequate Indian studies underscores the importance of pursuing research into HF in an Indian population. G protein-coupled receptor kinase 5 (GRK5) Gln41>Leu (rs2230345) polymorphism was reported as a genetic modifier associated with survival in HF patients. A prospective study was conducted to investigate the association of GRK5 Gln41>Leu polymorphism with response to β-blocker therapy in Indian HF patients.
Methods: HF patients (n=584) were recruited for the study. The patients were genotyped by tetra-primerbased allele specific PCR and confirmed with Sanger sequencing. The HF patients were evaluated for GRK5 gene expression and followed-up for ~3 years. Drug dosages, cardiac output and hospitalization-free survival were evaluated as study outcomes. HF subgroups (i.e.,systolic or diastolic dysfunction, biventricular dysfunction and pulmonary artery hypertension)were also analyzed in association with hospital-free survival.
Results: HF patients showed genotype frequencies of AT (15%) and TT (1%). AT/TT genotype carriers showed downregulated GRK5 gene expression and significant reduction in carvedilol drug dosage (p=0.0001). Moreover, AT/TT genotype carriers on β-blockers showed improved ejection fraction from 27% to 36% (p=0.0007) and increased hospitalization-free survival in comparison to other HF patients. HF patients with AA genotype showed an increased rate of hospital admission in comparison with patients with the AT/TT genotype. HF subgroups with the AT/TT genotype showed an increased hospitalization-free survival versus subgroups with the AA genotype.
Conclusions: GRK5 Gln41>Leu polymorphism in response to β-blocker therapy improved cardiac function in HF patients.
Relevance for patients: This study presents a comprehensive clinicofunctional pharmacogenetic characterization of GRK5 Gln41>Leu polymorphism in a cohort of Indian HF patients. GRK5 Gln41>Leu polymorphism can confer improved cardiac function and reduce hospitalization, thus improving the quality of life in HF patients.
DOI: http://dx.doi.org/10.18053/jctres.07.202104.010
Author affiliation
1.PSG Center for Molecular Medicine & Therapeutics, PSG Institute of Medical Sciences & Research, Coimbatore, Tamil Nadu, India.
2. Department of Cardiology, PSG Hospitals, Coimbatore, Tamil Nadu, India.
*Corresponding author
Sudha Ramalingam and Ramalingam Sankaran
PSG Center for Molecular Medicine and Therapeutics, PSG Institute of Medical Sciences & Research, Coimbatore - 641 004, Tamil Nadu, India.
Tel: +91 422- 598822, +91 9894618450
Fax:+91 422- 2594400
Email: drsudhapsg@gmail.com
Handling editor:
Michal Heger
Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China
Downloads
Full text PDF
Review process file (233.2 KB)
